Monopar Therapeutics — Director's Dealing 2018

Jan 8, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Monopar Therapeutics (NONE)
CIK: 0001645469
Period of Report: 2018-01-08

Reporting Person: Anderson Kirsten (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock options	$6.00		Common stock (40000)		Direct

Footnotes

F1: Reflects the issuance of options to purchase up to 40,000 shares of common stock granted to Ms. Anderson on November 1, 2017 for her services as an officer of Monopar Therapeutics. The options vest 6/48ths on the six-month anniversary of the grant date and 1/48th on each subsequent one-month anniversary thereafter. The options each expire on October 31, 2027.